Works matching AU Braña, Irene

Results: 25
    1

    A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.

    Published in:
    2017
    By:
    • Wainberg, Zev;
    • Alsina, Maria;
    • Soares, Heloisa;
    • Braña, Irene;
    • Britten, Carolyn;
    • Conte, Gianluca;
    • Ezeh, Patrick;
    • Houk, Brett;
    • Kern, Kenneth;
    • Leong, Stephen;
    • Pathan, Nuzhat;
    • Pierce, Kristen;
    • Siu, Lillian;
    • Vermette, Jennifer;
    • Tabernero, Josep;
    • Wainberg, Zev A;
    • Soares, Heloisa P;
    • Braña, Irene;
    • Britten, Carolyn D;
    • Del Conte, Gianluca
    Publication type:
    journal article
    2

    Emerging Immunotherapy Targets in Early Drug Development.

    Published in:
    International Journal of Molecular Sciences, 2025, v. 26, n. 11, p. 5394, doi. 10.3390/ijms26115394
    By:
    • Morchón-Araujo, Daniel;
    • Catani, Greta;
    • Mirallas, Oriol;
    • Pretelli, Giulia;
    • Sánchez-Pérez, Vicky;
    • Vieito, María;
    • Braña, Irene;
    • Pujol-Borrell, Ricardo;
    • Garralda, Elena;
    • Hernando-Calvo, Alberto
    Publication type:
    Article
    3
    4

    Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.

    Published in:
    JNCI Cancer Spectrum, 2020, v. 4, n. 2, p. 1, doi. 10.1093/jncics/pkz093
    By:
    • Piha-Paul, Sarina A;
    • Hann, Christine L;
    • French, Christopher A;
    • Cousin, Sophie;
    • Braña, Irene;
    • Cassier, Phillippe A;
    • Moreno, Victor;
    • Bono, Johann S de;
    • Harward, Sara Duckworth;
    • Ferron-Brady, Geraldine;
    • Barbash, Olena;
    • Wyce, Anastasia;
    • Wu, Yuehui;
    • Horner, Thierry;
    • Annan, Meg;
    • Parr, Nigel J;
    • Prinjha, Rabinder K;
    • Carpenter, Christopher L;
    • Hilton, John;
    • Hong, David S
    Publication type:
    Article
    5
    6

    Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

    Published in:
    Clinical & Translational Oncology, 2022, v. 24, n. 10, p. 1890, doi. 10.1007/s12094-022-02856-1
    By:
    • Trigo, José;
    • García-Cosío, Mónica;
    • García-Castaño, Almudena;
    • Gomà, Montserrat;
    • Mesia-Nin, Ricard;
    • Ruiz-Bravo, Elena;
    • Soria-Rivas, Ainara;
    • Castillo, Paola;
    • Braña-García, Irene;
    • Alberola-Ferranti, Margarita
    Publication type:
    Article
    7

    Homologous Recombination Deficiency (HRD) as a Potential Pan-Cancer Biomarker for PARP Inhibition.

    Published in:
    Journal of Immunotherapy & Precision Oncology, 2024, v. 7, n. 3, p. 241, doi. 10.36401/JIPO-24-X2
    By:
    • Hernando-Calvo, Alberto;
    • Romero, Paula;
    • Saavedra, Omar;
    • Catalogne, Francesca;
    • Oberoi, Arjun;
    • Alonso, Guzman;
    • Mirallas, Oriol;
    • Vieito, Maria;
    • Braña, Irene;
    • Lostes, Julia;
    • Galvão, Vladimir;
    • Pretelli, Giulia;
    • Ortega, Belen;
    • Aguilar, Susana;
    • Dienstmann, Rodrigo;
    • Garralda, Elena;
    • Vivancos, Ana;
    • Serrano, César
    Publication type:
    Article
    8

    Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.

    Published in:
    Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36399-y
    By:
    • Harding, James J.;
    • Piha-Paul, Sarina A.;
    • Shah, Ronak H.;
    • Murphy, Jessica J.;
    • Cleary, James M.;
    • Shapiro, Geoffrey I.;
    • Quinn, David I.;
    • Braña, Irene;
    • Moreno, Victor;
    • Borad, Mitesh;
    • Loi, Sherene;
    • Spanggaard, Iben;
    • Park, Haeseong;
    • Ford, James M.;
    • Arnedos, Mónica;
    • Stemmer, Salomon M.;
    • de la Fouchardiere, Christelle;
    • Fountzilas, Christos;
    • Zhang, Jie;
    • DiPrimeo, Daniel
    Publication type:
    Article
    9

    Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.

    Published in:
    Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36399-y
    By:
    • Harding, James J.;
    • Piha-Paul, Sarina A.;
    • Shah, Ronak H.;
    • Murphy, Jessica J.;
    • Cleary, James M.;
    • Shapiro, Geoffrey I.;
    • Quinn, David I.;
    • Braña, Irene;
    • Moreno, Victor;
    • Borad, Mitesh;
    • Loi, Sherene;
    • Spanggaard, Iben;
    • Park, Haeseong;
    • Ford, James M.;
    • Arnedos, Mónica;
    • Stemmer, Salomon M.;
    • de la Fouchardiere, Christelle;
    • Fountzilas, Christos;
    • Zhang, Jie;
    • DiPrimeo, Daniel
    Publication type:
    Article
    10

    Public and patient involvement: a survey on knowledge, experience and opinions among researchers within a precision oncology European project.

    Published in:
    BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11262-x
    By:
    • Mosconi, Paola;
    • Colombo, Cinzia;
    • Paletta, Pasquale;
    • Gangeri, Laura;
    • Pellegrini, Chiara;
    • Garralda, Elena;
    • Miceli, Rosalba;
    • Brunelli, Cinzia;
    • Braña, Irene;
    • Rodon, Jordi;
    • Villacampa, Guillermo;
    • Pedrola, Anna;
    • Dienstmann, Rodrigo;
    • Pont, Bianca;
    • Lostes, Júlia;
    • Piris, Alejandro;
    • Chavarria, Elena;
    • Villalobos, Xenia;
    • Colldeforns, Berta;
    • Pérez-López, Raquel
    Publication type:
    Article
    11

    Head and Neck Cancer in Fanconi Anemia: Report of 11 Cases and a Systematic Review.

    Published in:
    Cancers, 2025, v. 17, n. 3, p. 349, doi. 10.3390/cancers17030349
    By:
    • de Pablo García-Cuenca, Alba;
    • Rofín-Fontanet, Pau;
    • Lorente-Guerrero, Juan;
    • Balmaña-Gelpí, Judith;
    • Carrasco-López, Estela;
    • Temprana-Salvador, Jordi;
    • Granado-Carrasco, Raquel;
    • Braña-García, Irene;
    • Vaquero-Martínez, Pablo;
    • Pujol-Pina, Rosa;
    • Bescós-Atín, Coro
    Publication type:
    Article
    12
    13

    Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study.

    Published in:
    International Journal of Cancer, 2022, v. 150, n. 6, p. 993, doi. 10.1002/ijc.33861
    By:
    • Cousin, Sophie;
    • Blay, Jean‐Yves;
    • Garcia, Irene Braña;
    • de Bono, Johann S.;
    • Le Tourneau, Christophe;
    • Moreno, Victor;
    • Trigo, Jose;
    • Hann, Christine L.;
    • Azad, Arun A.;
    • Im, Seock‐Ah;
    • Cassier, Philippe A.;
    • French, Christopher A.;
    • Italiano, Antoine;
    • Keedy, Vicki L.;
    • Plummer, Ruth;
    • Sablin, Marie‐Paule;
    • Hemming, Matthew L.;
    • Ferron‐Brady, Geraldine;
    • Wyce, Anastasia;
    • Khaled, Ahmed
    Publication type:
    Article
    14

    Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors.

    Published in:
    Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-53265-7
    By:
    • Román Alonso, Macarena;
    • Grinyó-Escuer, Ariadna;
    • Duro-Sánchez, Santiago;
    • Rius-Ruiz, Irene;
    • Bort-Brusca, Marta;
    • Escorihuela, Marta;
    • Maqueda-Marcos, Susana;
    • Pérez-Ramos, Sandra;
    • Gago, Judit;
    • Nogales, Vanesa;
    • Espinosa-Bravo, Martín;
    • Peg, Vicente;
    • Escrivá-de-Romaní, Santiago;
    • Foradada, Laia;
    • Soucek, Laura;
    • Braña, Irene;
    • Galvao, Vladimir;
    • Martín-Lluesma, Silvia;
    • Moessner, Ekkehard;
    • Klein, Christian
    Publication type:
    Article
    15

    Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.

    Published in:
    BMC Cancer, 2024, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11316-0
    By:
    • Cho, Byoung Chul;
    • Braña, Irene;
    • Cirauqui, Beatriz;
    • Aksoy, Sercan;
    • Couture, Felix;
    • Hong, Ruey-Long;
    • Miller Jr, Wilson H.;
    • Chaves-Conde, Manuel;
    • Teixeira, Margarida;
    • Leopold, Lance;
    • Munteanu, Mihaela;
    • Ge, Joy Yang;
    • Swaby, Ramona F.;
    • Hughes, Brett G. M.
    Publication type:
    Article
    16

    Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival.

    Published in:
    NPJ Precision Oncology, 2021, v. 5, n. 1, p. 1, doi. 10.1038/s41698-021-00171-6
    By:
    • Lazar, Vladimir;
    • Magidi, Shai;
    • Girard, Nicolas;
    • Savignoni, Alexia;
    • Martini, Jean-François;
    • Massimini, Giorgio;
    • Bresson, Catherine;
    • Berger, Raanan;
    • Onn, Amir;
    • Raynaud, Jacques;
    • Wunder, Fanny;
    • Berindan-Neagoe, Ioana;
    • Sekacheva, Marina;
    • Braña, Irene;
    • Tabernero, Josep;
    • Felip, Enriqueta;
    • Porgador, Angel;
    • Kleinman, Claudia;
    • Batist, Gerald;
    • Solomon, Benjamin
    Publication type:
    Article
    17

    LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8<sup>+</sup> T cell tumor-infiltration impairing anti-PD1 therapy.

    Published in:
    Nature Communications, 2019, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41467-019-10369-9
    By:
    • Pascual-García, Mónica;
    • Bonfill-Teixidor, Ester;
    • Planas-Rigol, Ester;
    • Rubio-Perez, Carlota;
    • Iurlaro, Raffaella;
    • Arias, Alexandra;
    • Cuartas, Isabel;
    • Sala-Hojman, Ada;
    • Escudero, Laura;
    • Martínez-Ricarte, Francisco;
    • Huber-Ruano, Isabel;
    • Nuciforo, Paolo;
    • Pedrosa, Leire;
    • Marques, Carolina;
    • Braña, Irene;
    • Garralda, Elena;
    • Vieito, María;
    • Squatrito, Massimo;
    • Pineda, Estela;
    • Graus, Francesc
    Publication type:
    Article
    18
    19
    20

    Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 5, p. 1275, doi. 10.1007/s10637-020-01025-x
    By:
    • Olmedo, María Eugenia;
    • Forster, Martin;
    • Moreno, Victor;
    • López-Criado, María Pilar;
    • Braña, Irene;
    • Flynn, Michael;
    • Doger, Bernard;
    • de Miguel, María;
    • López-Vilariño, José Antonio;
    • Núñez, Rafael;
    • Kahatt, Carmen;
    • Cullell-Young, Martin;
    • Zeaiter, Ali;
    • Calvo, Emiliano
    Publication type:
    Article
    21
    22

    Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.

    Published in:
    2015
    By:
    • Rodón, Jordi;
    • Carducci, Michael;
    • Sepulveda-Sánchez, Juan;
    • Azaro, Analía;
    • Calvo, Emiliano;
    • Seoane, Joan;
    • Braña, Irene;
    • Sicart, Elisabet;
    • Gueorguieva, Ivelina;
    • Cleverly, Ann;
    • Pillay, N.;
    • Desaiah, Durisala;
    • Estrem, Shawn;
    • Paz-Ares, Luis;
    • Holdhoff, Matthias;
    • Blakeley, Jaishri;
    • Lahn, Michael;
    • Baselga, Jose
    Publication type:
    Journal Article
    23

    Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.

    Published in:
    Investigational New Drugs, 2015, v. 33, n. 2, p. 357, doi. 10.1007/s10637-014-0192-4
    By:
    • Rodón, Jordi;
    • Carducci, Michael;
    • Sepulveda-Sánchez, Juan;
    • Azaro, Analía;
    • Calvo, Emiliano;
    • Seoane, Joan;
    • Braña, Irene;
    • Sicart, Elisabet;
    • Gueorguieva, Ivelina;
    • Cleverly, Ann;
    • Pillay, N.;
    • Desaiah, Durisala;
    • Estrem, Shawn;
    • Paz-Ares, Luis;
    • Holdhoff, Matthias;
    • Blakeley, Jaishri;
    • Lahn, Michael;
    • Baselga, Jose
    Publication type:
    Article
    24
    25